US 12,000,833 B2
Marker for predicting the sensitivity to PI3K inhibitors
Julie Guillermet-Guibert, Toulouse (FR); Thibaut Douche, Toulouse (FR); Emmanuelle Mouton-Barbosa, Toulouse (FR); Odile Schiltz, Toulouse (FR); Marie-Pierre Bousquet, Toulouse (FR); and Célia Cintas, Toulouse (FR)
Assigned to INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), Paris (FR); UNIVERSITE PAUL SABATIER TOULOUSE III, Toulouse (FR); and CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), Paris (FR)
Appl. No. 16/765,345
Filed by INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), Paris (FR); UNIVERSITÉ PAUL SABATIER TOULOUSE III, Toulouse (FR); and CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), Paris (FR)
PCT Filed Nov. 22, 2018, PCT No. PCT/EP2018/082245
§ 371(c)(1), (2) Date May 19, 2020,
PCT Pub. No. WO2019/101871, PCT Pub. Date May 31, 2019.
Claims priority of application No. 17306625 (EP), filed on Nov. 23, 2017.
Prior Publication US 2020/0355693 A1, Nov. 12, 2020
Int. Cl. C07K 16/32 (2006.01); C07K 16/30 (2006.01); G01N 33/574 (2006.01); A61K 45/06 (2006.01); C07K 7/08 (2006.01)
CPC G01N 33/57438 (2013.01) [C07K 16/303 (2013.01); C07K 16/32 (2013.01); A61K 45/06 (2013.01); C07K 7/08 (2013.01)] 1 Claim
 
1. A method of treating pancreatic cancer in a subject in need thereof comprising
i) detecting a phosphopeptide having the amino acid sequence as set forth in SEQ ID NO:1 (PGTPSDHQSQEASQFER) wherein the threonine residue at position 3 is phosphorylated in a tumor tissue obtained from the subject and
ii) administering to the subject a therapeutically effective amount of a small molecule p110α and/or small molecule p110γ inhibitor when the phosphopeptide is detected at step i),
wherein the step of detecting is performed by SILAC based LC-MS/MS.